Purpose. The efficacy and safety of i.v. alteplase up to 4.5 hours after acute ischemic stroke (AIS) onset were evaluated. Summary. Stroke is the leading cause of disability in the elderly, and i.v.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Stroke patients ...

The American Heart Association/American Stroke Association has issued a new scientific statement on the rationale for the inclusion and exclusion criteria for intravenous alteplase (tissue plasminogen ...

A three month treatment with 300 mg IV aspirin does not improve the functional outcome of alteplase-treated acute ischemic stroke patients. However, the risk of developing SICH and SAEs is enhanced.

Recent use of direct oral anticoagulants (DOACs) does not seem to be associated with increased risk of intracranial hemorrhage among patients with acute ischemic stroke treated with intravenous ...

In 2001, the US Food and Drug Administration approved recombinant tissue plasminogen activator (alteplase, Cathflo Activase) to reestablish patency of central catheters occluded, presumably, by a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio CHICAGO — Intracoronary alteplase ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window DALLAS -- Dual ...

Whether the evidence supports wider use of tenecteplase (TNKase; Genentech)—a thrombolytic agent with an indication for acute MI—as an alternative to alteplase (Activase; Genentech) for the treatment ...

Fourteen randomised controlled trials (RCTs) comparing thrombolytic drugs were included in the review. Overall the studies were considered to be of excellent quality. In total, the trials involved ...